keyword
MENU ▼
Read by QxMD icon Read
search

ctDNA

keyword
https://www.readbyqxmd.com/read/29454952/probing-the-interaction-of-the-phytochemical-6-gingerol-from-the-spice-ginger-with-dna
#1
Poovvathingal Haris, Varughese Mary, Chellappanpillai Sudarsanakumar
6-Gingerol [5-hydroxy-1-(4-hydroxy-3-methoxyphenyl) decan-3-one], the bio-active ingredient of the popular Indian spice ginger (Zingiber officinale Roscoe), is well-known for its pharmacological and physiological actions. The potent antioxidant, antiemetic, antiulcer, antimicrobial, analgesic, hypoglycemic, antihypertensive, antihyperlipidemic, immunostimulant, anti-inflammatory, cardiotonic, and cancer prevention activities of 6-Gingerol has been investigated and explored. 6-Gingerol is a good candidate for the treatment of various cancers including prostrate, pancreatic, breast, skin, gastrointestinal, pulmonary, and renal cancer...
February 15, 2018: International Journal of Biological Macromolecules
https://www.readbyqxmd.com/read/29449275/circulating-tumor-dna-reveals-genetics-clonal-evolution-and-residual-disease-in-classical-hodgkin-lymphoma
#2
Valeria Spina, Alessio Bruscaggin, Annarosa Cuccaro, Maurizio Martini, Martina Di Trani, Gabriela Forestieri, Martina Manzoni, Adalgisa Condoluci, Alberto Arribas, Lodovico Terzi-Di-Bergamo, Silvia Laura Locatelli, Elisa Cupelli, Luca Ceriani, Alden A Moccia, Anastasios Stathis, Luca Nassi, Clara Deambrogi, Fary Diop, Francesca Guidetti, Alessandra Cocomazzi, Salvatore Annunziata, Vittoria Rufini, Alessandro Giordano, Antonino Neri, Renzo Boldorini, Bernhard Gerber, Francesco Bertoni, Michele Ghielmini, Georg Stüssi, Armando Santoro, Franco Cavalli, Emanuele Zucca, Luigi Maria Larocca, Gianluca Gaidano, Stefan Hohaus, Carmelo Carlo-Stella, Davide Rossi
The rarity of neoplastic cells in the biopsy imposes major technical hurdles that have so far limited genomic studies in classical Hodgkin lymphoma (cHL). By using a highly sensitive and robust deep-next-generation-sequencing approach for circulating tumor DNA (ctDNA), here we aimed at tracking the genetics of cHL in different clinical phases, and its modifications upon treatment. The analysis was based on specimens collected from 80 newly diagnosed and 32 refractory cHL patients, including longitudinal samples collected under ABVD chemotherapy and longitudinal samples from relapsing patients treated with chemotherapy and immunotherapy...
February 15, 2018: Blood
https://www.readbyqxmd.com/read/29449271/targeted-therapies-for-targeted-populations-anti-egfr-treatment-for-egfr-amplified-gastroesophageal-adenocarcinoma
#3
Steven B Maron, Lindsay Alpert, Heewon A Kwak, Samantha Lomnicki, Leah Chase, David Xu, Emily O'Day, Rebecca J Nagy, Richard B Lanman, Fabiola Cecchi, Todd Hembrough, Alexa Schrock, John Hart, Shu-Yuan Xiao, Namrata Setia, Daniel V T Catenacci
Previous anti-EGFR trials in unselected gastroesophageal adenocarcinoma (GEA) patients were resoundingly negative. We identified EGFR amplification in 5% (19/363) of patients at the University of Chicago, including 6% (8/140) who were prospectively screened with intention-to-treat using anti-EGFR therapy. Seven pts received >1 dose of treatment: three first line FOLFOX plus ABT-806, one second line FOLFIRI plus cetuximab, and three third/fourth line cetuximab alone. Treatment achieved objective response in 58% (4/7) and disease control in 100% (7/7) with a median progression-free survival of 10 months...
February 15, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/29441780/extending-circulating-tumour-dna-analysis-to-ultra-low-abundance-mutations-techniques-and-challenges
#4
Andrew Edwin Rodda, Bradyn Jared Parker, Andrew Spencer, Simon Robert Corrie
Liquid biopsies that analyse ctDNA hold great promise in the guidance of clinical treatment for various cancers. However, the innate characteristics of ctDNA make it a difficult target: ctDNA is highly fragmented, and found at very low concentrations, both in absolute terms and relative to wildtype species. Clinically-relevant target sequences often differ from the wildtype species by a single DNA base pair. These characteristics make analysing mutant ctDNA a uniquely difficult process. Despite this, techniques have recently emerged for analysing ctDNA, and have been used in pilot studies that showed promising results...
February 14, 2018: ACS Sensors
https://www.readbyqxmd.com/read/29441349/liquid-biopsy-in-clinical-management-of-breast-lung-and-colorectal-cancer
#5
REVIEW
Ivana Bratić Hench, Jürgen Hench, Markus Tolnay
Examination of tumor molecular characteristics by liquid biopsy is likely to greatly influence personalized cancer patient management. Analysis of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and tumor-derived exosomes, all collectively referred to as "liquid biopsies," are not only a modality to monitor treatment efficacy, disease progression, and emerging therapy resistance mechanisms, but they also assess tumor heterogeneity and evolution in real time. We review the literature concerning the examination of ctDNA and CTC in a diagnostic setting, evaluating their prognostic, predictive, and monitoring capabilities...
2018: Frontiers in Medicine
https://www.readbyqxmd.com/read/29438522/ras-mutation-analysis-in-circulating-tumor-dna-from-patients-with-metastatic-colorectal-cancer-the-ageo-rasanc-prospective-multicenter-study
#6
J B Bachet, O Bouché, J Taieb, O Dubreuil, M L Garcia, A Meurisse, C Normand, J M Gornet, P Artru, S Louafi, F Bonnetain, A Thirot-Bidault, I Baumgaertner, R Coriat, D Tougeron, T Lecomte, F Mary, T Aparicio, L Marthey, V Taly, H Blons, D Vernerey, P Laurent-Puig
Background: RAS mutations are currently sought for in tumor samples, which takes a median of almost 3 weeks in western European countries. This creates problems in clinical situations that require urgent treatment and for inclusion in therapeutic trials that need RAS status for randomization. Analysis of circulating tumor DNA might help to shorten the time required to determine RAS mutational status prior to anti-EGFR antibody therapy for metastatic colorectal cancer. Here we compared plasma versus tissue RAS analysis in a large prospective multicenter cohort...
February 9, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29437753/dynamic-changes-of-circulating-tumour-dna-in-surgical-lung-cancer-patients-protocol-for-a-prospective-observational-study
#7
Kezhong Chen, Heng Zhao, Fan Yang, Bengang Hui, Tianyang Wang, Lieu Tu Wang, Yanbin Shi, Jun Wang
INTRODUCTION: Circulating tumour DNA (ctDNA) has potential applications in cancer management. Most previous studies about ctDNA focused on advanced stage cancer patients. We have completed a clinical prospective study (NCT02645318) and showed the feasibility and clinical application of ctDNA detection in early stage non-small cell lung cancer (NSCLC) patients. The aim of this study is to investigate the elimination rate of ctDNA level after surgery. This is the first prospective study to evaluate the perioperative dynamic changes of ctDNA in surgical lung cancer patients...
February 6, 2018: BMJ Open
https://www.readbyqxmd.com/read/29434880/clinical-significance-of-brafv600e-mutation-in-circulating-tumor-dna-in-chinese-patients-with-melanoma
#8
Huan Tang, Yan Kong, Lu Si, Chuanliang Cui, Xinan Sheng, Zhihong Chi, Jie Dai, Sifan Yu, Meng Ma, Xiaowen Wu, Jiayi Yu, Tianxiao Xu, Huan Yu, Junya Yan, Jun Guo
The present study aimed to assess the B rapidly accelerated fibrosarcoma (BRAFV600E) status in plasma from Chinese patients with melanoma, and evaluated its prognostic value following treatment with BRAF inhibitors. Mutation-specific 3D digital polymerase chain reaction (dPCR) was used to quantify BRAFV600E in circulating tumor DNA (ctDNA) in 58 patients with melanoma, prior to treatment with BRAF inhibitors. Correlations between baseline ctDNA levels and clinicopathological characteristics and clinical benefits were then statistically analyzed...
February 2018: Oncology Letters
https://www.readbyqxmd.com/read/29430504/liquid-biopsy-analysis-of-circulating-tumor-dna-ctdna-in-bladder-cancer
#9
REVIEW
Tilman Todenhöfer, Werner J Struss, Roland Seiler, Alexander William Wyatt, Peter C Black
Recent advances in DNA profiling techniques have enabled sensitive detection of tumor-associated genomic aberrations in peripheral blood. This type of minimally-invasive molecular interrogation has the potential to guide subsequent treatment selection. The potential utility of ctDNA in bladder cancer (BC) is bolstered by the high somatic mutation rate, meaning that very small numbers of genes or target regions can be informative. First reports indicate that analysis of ctDNA may represent a sensitive method for disease surveillance in patients with different stages of BC...
January 20, 2018: Bladder Cancer
https://www.readbyqxmd.com/read/29423521/efficacy-of-sym004-in-patients-with-metastatic-colorectal-cancer-with-acquired-resistance-to-anti-egfr-therapy-and-molecularly-selected-by-circulating-tumor-dna-analyses-a-phase-2-randomized-clinical-trial
#10
Clara Montagut, Guillem Argilés, Fortunato Ciardiello, Thomas T Poulsen, Rodrigo Dienstmann, Michael Kragh, Scott Kopetz, Trine Lindsted, Cliff Ding, Joana Vidal, Jenifer Clausell-Tormos, Giulia Siravegna, Francisco J Sánchez-Martín, Klaus Koefoed, Mikkel W Pedersen, Michael M Grandal, Mikhail Dvorkin, Lucjan Wyrwicz, Ana Rovira, Antonio Cubillo, Ramon Salazar, Françoise Desseigne, Cristina Nadal, Joan Albanell, Vittorina Zagonel, Salvatore Siena, Guglielmo Fumi, Giuseppe Rospo, Paul Nadler, Ivan D Horak, Alberto Bardelli, Josep Tabernero
Importance: Acquired resistance to anti-EGFR therapy (epidermal growth factor receptor) is frequently due to RAS and EGFR extracellular domain (ECD) mutations in metastatic colorectal cancer (mCRC). Some anti-EGFR-refractory patients retain tumor EGFR dependency potentially targetable by agents such as Sym004, which is a mixture of 2 nonoverlapping monoclonal antibodies targeting EGFR. Objective: To determine if continuous blockade of EGFR by Sym004 has survival benefit...
February 8, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29423503/association-between-circulating-tumor-dna-and-pseudoprogression-in-patients-with-metastatic-melanoma-treated-with-anti-programmed-cell-death-1-antibodies
#11
Jenny H Lee, Georgina V Long, Alexander M Menzies, Serigne Lo, Alexander Guminski, Kataraina Whitbourne, Michelle Peranec, Richard Scolyer, Richard F Kefford, Helen Rizos, Matteo S Carlino
Importance: Longitudinal circulating tumor DNA (ctDNA) has been shown to predict response and survival in patients with metastatic melanoma treated with anti-programmed cell death 1 (PD-1) antibodies. Pseudoprogression, defined as radiologic finding of disease progression prior to response, has been a challenge to clinicians. Objective: To establish whether ctDNA at baseline and up to week 12 of treatment can differentiate between the radiologic findings of pseudoprogression and true progression in patients with metastatic melanoma...
February 8, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29420226/serial-circulating-tumour-dna-analysis-during-multimodality-treatment-of-locally-advanced-rectal-cancer-a-prospective-biomarker-study
#12
Jeanne Tie, Joshua D Cohen, Yuxuan Wang, Lu Li, Michael Christie, Koen Simons, Hany Elsaleh, Suzanne Kosmider, Rachel Wong, Desmond Yip, Margaret Lee, Ben Tran, David Rangiah, Matthew Burge, David Goldstein, Madhu Singh, Iain Skinner, Ian Faragher, Matthew Croxford, Carolyn Bampton, Andrew Haydon, Ian T Jones, Christos S Karapetis, Timothy Price, Mary J Schaefer, Jeanne Ptak, Lisa Dobbyn, Natallie Silliman, Isaac Kinde, Cristian Tomasetti, Nickolas Papadopoulos, Kenneth Kinzler, Bert Volgestein, Peter Gibbs
OBJECTIVE: For patients with locally advanced rectal cancer (LARC), adjuvant chemotherapy selection following surgery remains a major clinical dilemma. Here, we investigated the ability of circulating tumour DNA (ctDNA) to improve risk stratification in patients with LARC. DESIGN: We enrolled patients with LARC (T3/T4 and/or N+) planned for neoadjuvant chemoradiotherapy. Plasma samples were collected pretreatment, postchemoradiotherapy and 4-10 weeks after surgery...
February 2, 2018: Gut
https://www.readbyqxmd.com/read/29416754/targeted-deep-sequencing-of-circulating-tumor-dna-in-metastatic-pancreatic-cancer
#13
Andreas W Berger, Daniel Schwerdel, Thomas J Ettrich, Alexander Hann, Stefan A Schmidt, Alexander Kleger, Ralf Marienfeld, Thomas Seufferlein
Purpose: Precision medicine in pancreatic ductal adenocarcinoma (PDAC) could be substantially supported by tools that allow to establish and monitor the molecular setup of the tumor. In particular, noninvasive approaches are desirable, but not validated. Characterization of circulating tumor DNA (ctDNA) may help to achieve this goal. Experimental Design: Blood samples from patients with metastatic PDAC prior to and during palliative treatment were collected. ctDNA and corresponding tumor tissue were analyzed by targeted next generation sequencing and droplet digital PCR for the 7 most frequently mutated genes in PDAC (TP53, SMAD4, CDKN2A, KRAS, APC, ATM, and FBXW7)...
January 5, 2018: Oncotarget
https://www.readbyqxmd.com/read/29416630/prognostic-value-of-quantitative-ctdna-levels-in-non-small-cell-lung-cancer-patients
#14
Mariano Provencio, María Torrente, Virginia Calvo, David Pérez-Callejo, Lourdes Gutiérrez, Fernando Franco, Clara Pérez-Barrios, Miguel Barquín, Ana Royuela, Francisco García-García, Coralia Bueno, Aranzazu Garcia-Grande, Carlos Camps, Bartomeu Massuti, Eduardo Sotomayor, Atocha Romero
Background: Circulating tumor DNA (ctDNA) levels correlate well with tumor bulk. In this paper we aim to estimate the prognostic value of the dynamic quantification of ctDNA levels. Materials and Methods: A total of 251 serial plasma samples from 41 non-small-cell lung cancer patients who carried an activating EGFR mutation were analysed by digital PCR. For survival analysis, ctDNA levels were computed as a time-dependent covariate. Results: Dynamic ctDNA measurements had prognostic significance (hazard ratio for overall survival and progression free survival according to p...
January 2, 2018: Oncotarget
https://www.readbyqxmd.com/read/29413989/annonalide-and-derivatives-semisynthesis-cytotoxic-activities-and-studies-on-interaction-of-annonalide-with-dna
#15
Ricardo A Marques, Akenaton O C V Gomes, Maria V de Brito, Ana L P Dos Santos, Gladyane S da Silva, Leandro B de Lima, Fátima M Nunes, Marcos C de Mattos, Fátima C E de Oliveira, Cláudia do Ó Pessoa, Manoel O de Moraes, Ângelo de Fátima, Lucas L Franco, Marina de M Silva, Maria Dayanne de A Dantas, Josué C C Santos, Isis M Figueiredo, Edeíldo F da Silva-Júnior, Thiago M de Aquino, João X de Araújo-Júnior, Maria C F de Oliveira, A A Leslie Gunatilaka
The cytotoxic activity of the pimarane diterpene annonalide (1) and nine of its semisynthetic derivatives (2-10) was investigated against the human tumor cell lines HL-60 (leukemia), PC-3 (prostate adenocarcinoma), HepG2 (hepatocellular carcinoma), SF-295 (glioblastoma) and HCT-116 (colon cancer), and normal mouse fibroblast (L929) cells. The preparation of 2-10 involved derivatization of the side chain of 1 at C-13. Except for 2, all derivatives are being reported for the first time. Most of the tested compounds presented IC50s below 4...
February 1, 2018: Journal of Photochemistry and Photobiology. B, Biology
https://www.readbyqxmd.com/read/29405770/liquid-biopsy-and-its-role-in-an-advanced-clinical-trial-for-lung-cancer
#16
Donald J Johann, Mathew Steliga, Ik J Shin, Donghoon Yoon, Konstantinos Arnaoutakis, Laura Hutchins, Meeiyueh Liu, Jason Liem, Karl Walker, Andy Pereira, Mary Yang, Susanne K Jeffus, Erich Peterson, Joshua Xu
Liquid biopsy methodologies, for the purpose of plasma genotyping of cell-free DNA (cfDNA) of solid tumors, are a new class of novel molecular assays. Such assays are rapidly entering the clinical sphere of research-based monitoring in translational oncology, especially for thoracic malignancies. Potential applications for these blood-based cfDNA assays include: (i) initial diagnosis, (ii) response to therapy and follow-up, (iii) tumor evolution, and (iv) minimal residual disease evaluation. Precision medicine will benefit from cutting-edge molecular diagnostics, especially regarding treatment decisions in the adjuvant setting, where avoiding over-treatment and unnecessary toxicity are paramount...
February 2018: Experimental Biology and Medicine
https://www.readbyqxmd.com/read/29403309/a-comparison-of-quantstudio%C3%A2-3d-digital-pcr-and-arms-pcr-for-measuring-plasma-egfr-t790m-mutations-of-nsclc-patients
#17
Qin Feng, Fei Gai, Yaxiong Sang, Jie Zhang, Ping Wang, Yue Wang, Bing Liu, Dongmei Lin, Yang Yu, Jian Fang
Background: The AURA3 clinical trial has shown that advanced non-small cell lung cancer (NSCLC) patients with EGFR T790M mutations in circulating tumor DNA (ctDNA) could benefit from osimertinib. Purpose: The aim of this study was to assess the usefulness of QuantStudio™ 3D Digital PCR System platform for the detection of plasma EGFR T790M mutations in NSCLC patients, and compare the performances of 3D Digital PCR and ARMS-PCR. Patients and methods: A total of 119 Chinese patients were enrolled in this study...
2018: Cancer Management and Research
https://www.readbyqxmd.com/read/29400963/half-sandwich-iridium-iii-and-ruthenium-ii-complexes-containing-p-p-chelating-ligands-a-new-class-of-potent-anticancer-agents-with-unusual-redox-features
#18
JuanJuan Li, Meng Tian, Zhenzhen Tian, Shumiao Zhang, Chao Yan, Changfang Shao, Zhe Liu
A series of half-sandwich IrIII pentamethylcyclopentadienyl and RuII arene complexes containing P^P-chelating ligands of the type [(Cpx/arene)M(P^P)Cl]PF6, where M = Ir, Cpx is pentamethylcyclopentadienyl (Cp*), or 1-biphenyl-2,3,4,5-tetramethyl cyclopentadienyl (CpxbiPh); M = Ru, arene is 3-phenylpropan-1-ol (bz-PA), 4-phenylbutan-1-ol (bz-BA), or p-cymene (p-cym), and P^P is 2,20-bis(diphenylphosphino)-1,10-binaphthyl (BINAP), have been synthesized and fully characterized, three of them by X-ray crystallography, and their potential as anticancer agents explored...
February 5, 2018: Inorganic Chemistry
https://www.readbyqxmd.com/read/29400604/capture-based-ultra-deep-sequencing-in-plasma-ctdna-reveals-the-resistance-mechanism-of-alk-inhibitors-in-a-patient-with-advanced-alk-positive-nsclc
#19
Jing Guo, Lihong Guo, Li Sun, Zhenzhen Wu, Junyi Ye, Jing Liu, Qiang Zuo
BACKGROUND: Anaplastic lymphoma kinase (ALK) is a validated molecular target in non-small-cell lung cancer (NSCLC). However, the clinical benefits of ALK inhibitors are almost universally limited by the emergence of drug resistance. METHODS: We monitored the plasma circulating tumor DNA (ctDNA) using captured-based ultra-deep sequencing analysis of one patient with metastatic ALK-positive NSCLC who had received therapies including first-, second- and third-generation ALK inhibitors...
February 5, 2018: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/29397622/-current-situation-and-prospect-of-breast-cancer-liquid-biopsy
#20
B Zhou, L Xin, L Xu, J M Ye, Y H Liu
Liquid biopsy is a diagnostic approach by analyzing body fluid samples. Peripheral blood is the most common sample. Urine, saliva, pleural effusion and ascites are also used. Now liquid biopsy is mainly used in the area of neoplasm diagnosis and treatment. Compared with traditional tissue biopsy, liquid biopsy is minimally invasive, convenient to sample and easy to repeat. Liquid biopsy mainly includes circulating tumor cells and circulating tumor DNA (ctDNA) detection. Detection of ctDNA requires sensitive and accurate methods...
February 1, 2018: Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]
keyword
keyword
34533
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"